DYF1 Stock Overview
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DYF1 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.53 |
| 52 Week High | US$13.57 |
| 52 Week Low | US$8.60 |
| Beta | 1.23 |
| 1 Month Change | 4.20% |
| 3 Month Change | 5.43% |
| 1 Year Change | 11.73% |
| 3 Year Change | 25.30% |
| 5 Year Change | 262.56% |
| Change since IPO | -58.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| DYF1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 0.4% | -0.5% |
| 1Y | 11.7% | -13.0% | 13.3% |
Return vs Industry: DYF1 exceeded the German Biotechs industry which returned -11.8% over the past year.
Return vs Market: DYF1 underperformed the German Market which returned 14% over the past year.
Price Volatility
| DYF1 volatility | |
|---|---|
| DYF1 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: DYF1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DYF1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 405 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis.
Dynavax Technologies Corporation Fundamentals Summary
| DYF1 fundamental statistics | |
|---|---|
| Market cap | €1.56b |
| Earnings (TTM) | €25.24m |
| Revenue (TTM) | €256.26m |
62.8x
P/E Ratio6.2x
P/S RatioIs DYF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYF1 income statement (TTM) | |
|---|---|
| Revenue | US$277.25m |
| Cost of Revenue | US$108.26m |
| Gross Profit | US$168.99m |
| Other Expenses | US$141.68m |
| Earnings | US$27.31m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 60.95% |
| Net Profit Margin | 9.85% |
| Debt/Equity Ratio | 37.5% |
How did DYF1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/21 17:12 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dynavax Technologies Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Jason Butler | Citizens JMP Securities, LLC |
| Douglas Buchanan | Citizens JMP Securities, LLC |